348

BLADDER, PENIS AND URETHRAL CANCER, AND BASIC PRINCIPLES OF ONCOLOGY

Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology Re: Final Results of an EORTC-GU Cancers Group Randomized Study of rin in Intermediate- and High-Risk Ta, Maintenance Bacillus Calmette-Gue T1 Papillary Carcinoma of the Urinary Bladder: One-Third Dose versus Full Dose and 1 Year versus 3 Years of Maintenance J. Oddens, M. Brausi, R. Sylvester, A. Bono, C. van de Beek, G. van Andel, P. Gontero, W. Hoeltl, L. Turkeri, S. Marreaud, S. Collette and W. Oosterlinck Department of Urology, Jeroen Bosch Ziekenhuis, ’s-Hertogenbosch, The Netherlands Eur Urol 2013; 63: 462e472.

Abstract available at http://jurology.com/ Editorial Comment: Few patients can tolerate 3 years of maintenance bacillus Calmette-Guerin (BCG) therapy, and some become BCG bladder cripples, suffering from urgency, frequency and urge incontinence. Smaller phase II studies suggested that a third or even a tenth dose of BCG was as effective as a full dose and less toxic. This randomized trial shows that patients with high risk, nonmuscle invasive urothelial cancer need full dose BCG optimally for 3 years to decrease recurrence rates, although tumor progression and death were no different than with full dose BCG for 1 year. Surprisingly there was no difference in toxicity between a third and a full dose of BCG. David P. Wood, MD

Re: Role of Marker Lesion When Applying Intravesical Instillations of IL-2 for Non-Muscle-Invasive Bladder Cancer Comparison of the Therapeutic Effects in Two Pilot Studies W. Den Otter, R. J. Van Moorselaar, J. J. Jacobs, R. T. Haar, J. W. Koten, _ D. Characiejus, F. Jankevicius, Z. Dobrowolski, W. Lipczynski, V. Pa sukoniene, R. Eidukevi cius and T. M. De Reijke Department of Urology, Free University Medical Centre, Amsterdam, The Netherlands Anticancer Res 2013; 33: 2099e2105.

Abstract available at http://jurology.com/ Editorial Comment: Could immunotherapy be the next treatment for nonmuscle invasive urothelial cancer? It makes sense that the recurrence-free survival would be worse in the cohort with a marker lesion left in place, although the better time to recurrence in the marker lesion group may be related to the presence of tumor associated antigens (as the authors suggest), or it could be that if a complete response occurs with a marker lesion in the bladder, then the tumor is extremely sensitive to the immunotherapy and thus a reflection of effectiveness of the treatment. David P. Wood, MD

Re: role of marker lesion when applying intravesical instillations of IL-2 for non-muscle-invasive bladder cancer comparison of the therapeutic effects in two pilot studies.

Re: role of marker lesion when applying intravesical instillations of IL-2 for non-muscle-invasive bladder cancer comparison of the therapeutic effects in two pilot studies. - PDF Download Free
39KB Sizes 0 Downloads 0 Views